Vertex Pharmaceuticals
VRTX | NASDAQ
$559.41
+$19.41 (+3.59%)
At close: Oct 30, 2026, 4:00 PM ET
$561.49
+$2.08 (+0.37%)
Pre-market:
Nov 2, 2026, 9:28 AM ET
Market Data
Market Cap $141.79B
Enterprise Value $133.94B
Beta 0.32
Average Volume 1.37M
Shares Outstanding (Diluted) 255.7M
Shares Change YoY -1.24%
Institutional Ownership 95.84%
Exchange NASDAQ
ISIN US92532F1003
Price Performance
Price Change 1M 7.0%
Price Change 3M 17.3%
Price Change 6M 32.0%
Price Change YTD 23.4%
Price Change 1Y 31.4%
Price Change 3Y 54.5%
Price Change 5Y 202.5%
1M CAGR (ann.) 9.9%
1Y CAGR (ann.) 34.0%
5Y CAGR (ann.) 24.9%
All-Time CAGR 21.8%
Valuation
PE Ratio 32.56
Forward PE 27.23
PEG Ratio 1.43
Forward PEG 25.55
PS Ratio 11.23
Forward PS 9.70
PB Ratio 7.00
P/FCF Ratio 37.35
P/Adj. FCF Ratio 45.64
P/OCF Ratio 33.08
EV/Sales 10.61
EV/EBIT 25.36
EV/EBITDA 24.60
EV/FCF 35.28
Earnings Yield 3.1%
FCF Yield 2.7%
Adj. FCF Yield 2.2%
Financial Health
Net Cash $7.85B
Total Debt $0
Cash & Short-Term Investments $7.85B
Total Assets $27.42B
Current Ratio 3.19
Quick Ratio 2.74
Debt / Equity Ratio 0.10
Debt / EBITDA 0.00
Debt / FCF 0.00
OCF / Debt N/A
Interest Coverage 738.18
Altman Z-Score 14.12
Piotroski F-Score 5
Margins & Profitability
Gross Profit Margin 86.0%
Operating Profit Margin 38.6%
EBITDA Margin 43.6%
Net Profit Margin 34.9%
FCF Margin 30.1%
Adj. FCF Margin 24.6%
SBC / Revenue 5.5%
SBC Impact (per share) -18.1%
Returns
Return on Assets 16.1%
Return on Equity 23.3%
Return on Invested Capital 17.3%
Return on Capital Employed 20.7%
Return on Tangible Assets 17.0%
Historical Growth (CAGR)
Revenue CAGR 3Y 9.9%
Revenue CAGR 5Y 13.6%
Revenue CAGR 10Y 23.3%
EPS CAGR 3Y 9.9%
EPS CAGR 5Y 17.8%
EPS CAGR 10Y 14.9%
FCF CAGR 3Y -0.7%
FCF CAGR 5Y 16.4%
FCF CAGR 10Y 11.5%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 22
EPS Growth Next 3Y 20.0%
Revenue Growth Next 3Y 13.7%
Earnings Date Nov 2, 2026
EPS Estimate (next Q) $4.82
EPS Growth Est (next Q) 0.4%
Revenue Est (next Q) $3.42B
Revenue Growth Est (next Q) 11.1%
Fair Value Estimates
Graham Number $175.58
Graham Upside -68.6%
Lynch Fair Value $305.46
Lynch Upside -45.4%
Price Target $573.50
Price Target Upside 2.5%
Cash Flow
Operating Cash Flow $4.29B
Free Cash Flow $3.8B
Adj. Free Cash Flow $3.11B
FCF Per Share $14.95
OCF Per Share $16.91
OCF/S Ratio 34.0%
Income Statement
Revenue $12.62B
Gross Profit $10.86B
Operating Income $4.87B
EBITDA $5.44B
Net Income $4.41B
EPS (Diluted) $17.18
Revenue / Employee $1.97M
Profit / Employee $688.31K
Employees 6,400
Add to Watchlist
Select watchlists to add or remove VRTX